The early diagnosis and treatment of cholangiocarcinoma may benefit from specific tumor markers to be used in clinical practice.
To investigate whether the pGCsiRNA-vascular endothelial growth factor (VEGF) can affect the onset and progression of cholangiocarcinoma and its possible mechanism using the targeted therapy of nude mouse model of cholangiocarcinoma with attenuated
The nude mouse model of cholangiocarcinoma was established by tail vein injection of QBC939 cells and given attenuated
The tumor volume and weight of the pGCsiRNA-VEGF group were significantly smaller than those of the mock and the si-scramble groups (
In vivo silencing of VEGF can affect cell survival and inhibit cell migration, invasion, and development, probably by enhancing apoptosis and inhibiting the expressions of MMP2 and MMP9.